Home > Rheumatology > EULAR 2020 > COVID-19 > COVID-19 and inflammatory rheumatic disease: some key issues

COVID-19 and inflammatory rheumatic disease: some key issues

The currently available data suggests that patients with inflammatory rheumatic conditions do not exhibit an increased frequency of COVID-19 infection or a more severe course of the disease in general. General risk factors –such as older age, obesity, cardiovascular conditions, chronic lung conditions, hypertension, and diabetes– seem to be much more important in this respect.

During a unique virtual press conference, Prof. Gerd Burmester (EULAR Public Affairs Officer; Charité University Hospital, Germany) addressed some issues regarding medication, inflammatory rheumatic disease, and COVID-19 infection [1]. He emphasised that discontinuing immunomodulatory medication is not a good idea, as patients with inflammatory rheumatic diseases do not have an increased frequency of infection with COVID-19, nor do they experience a more severe course of the infection. Moreover, stopping therapy may trigger a relapse of the disease, which may lead to an unfavourable ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on